» Articles » PMID: 37436934

Women with PCOS Have an Increased Risk for Cardiovascular Disease Regardless of Diagnostic Criteria-a Prospective Population-based Cohort Study

Overview
Specialty Endocrinology
Date 2023 Jul 12
PMID 37436934
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Polycystic ovary syndrome (PCOS) is associated with many cardiovascular disease (CVD) risk factors, such as obesity, type 2 diabetes mellitus and hypertension. However, it remains debatable whether the presence of multiple CVD risk factors translates to increased CVD events.

Design: A prospective, population-based Northern Finland Birth Cohort 1966.

Methods: Individuals with an expected date of birth in 1966 in Northern Finland have been followed from birth. Women in the cohort were classified as having PCOS according to either the National Institute of Health (NIH) criteria (n = 144) or the Rotterdam criteria (n = 386) at age 31, and they were compared to women without any PCOS features. The study population was re-examined at age 46, and the incidence of major adverse cardiovascular events (MACE), including myocardial infarction (MI), stroke, heart failure and cardiovascular mortality, was recorded up to age 53.

Results: During the 22-year follow-up, both women with NIH-PCOS and women with Rotterdam-PCOS had a significantly higher risk for cardiovascular events than control women. The BMI-adjusted hazard ratio (HR) for MACE in the Rotterdam-PCOS group and the NIH-PCOS group was 2.33 (1.26-4.30) and 2.47 (1.18-5.17), respectively. The cumulative hazard curves in both diagnostic categories began to diverge at age 35. Regarding the individual CVD endpoints, MI was significantly more prevalent in both women with NIH-PCOS (P = .010) and women with Rotterdam-PCOS (P = .019), when compared to control women.

Conclusions: PCOS should be considered a significant risk factor for CVD. Future follow-up will show how the risk of CVD events develops after menopausal age.

Citing Articles

Cardiovascular disease risk prediction by Framingham risk score in women with polycystic ovary syndrome.

Amiri M, Mousavi M, Noroozzadeh M, Azizi F, Ramezani Tehrani F Reprod Biol Endocrinol. 2025; 23(1):19.

PMID: 39905496 PMC: 11792350. DOI: 10.1186/s12958-025-01346-7.


Cardiovascular Risk Biomarkers in Women with and Without Polycystic Ovary Syndrome.

Nandakumar M, Das P, Sathyapalan T, Butler A, Atkin S Biomolecules. 2025; 15(1).

PMID: 39858399 PMC: 11763313. DOI: 10.3390/biom15010004.


Polycystic Ovary Syndrome and Eating Disorders-A Literature Review.

Goral A, Zywot K, Zalewski W, Jagodzinski A, Murawski M J Clin Med. 2025; 14(1.

PMID: 39797110 PMC: 11720544. DOI: 10.3390/jcm14010027.


Adropin/Tirzepatide Combination Mitigates Cardiac Metabolic Aberrations in a Rat Model of Polycystic Ovarian Syndrome, Implicating the Role of the AKT/GSK3β/NF-κB/NLRP3 Pathway.

Hegab I, El-Horany H, Abd-Ellatif R, Nasef N, Okasha A, Emam M Int J Mol Sci. 2025; 26(1.

PMID: 39795860 PMC: 11720588. DOI: 10.3390/ijms26010001.


Development and validation of a model to identify polycystic ovary syndrome in the French national administrative health database.

Micolon E, Loubiere S, Zimmermann A, Berbis J, Auquier P, Courbiere B BMC Med Res Methodol. 2025; 25(1):5.

PMID: 39794688 PMC: 11721591. DOI: 10.1186/s12874-024-02447-4.